Adjuvant TACE Combined with Tislelizumab and Donafenib for High-Risk Hepatocellular Carcinoma After Curative Resection (TIDE): A Phase II Study
Abstract Hepatocellular carcinoma (HCC) frequently recurs after curative resection, particularly in patients with large tumors and microvascular invasion (MVI). An effective adjuvant therapy for patients with these features remains uncertain. Combining transarterial chemoembolization (TACE) with systemic therapy has shown activity in unresectable HCC, but its role after resection is unclear. Here we report a prospective, single-center, single-arm phase II study (TIDE; ChiCTR2200063003) of one postoperative TACE session followed by one year of tislelizumab and donafenib in patients with a solitary HCC larger than 5 cm and pathologically confirmed MVI. Among 30 patients, the estimated 3-year recurrence-free survival rate, the primary endpoint, was 56.7% (95% confidence interval, 37.3–72.1%) after a median follow-up of 38.7 months. The estimated 3-year overall survival rate was 93.3% (95% confidence interval, 75.9–98.3%). Grade 3 or higher treatment-related adverse events occurred in eight patients (26.7%), and there were no treatment-related deaths. This study show that adjuvant TACE combined with tislelizumab and donafenib is a feasible treatment option for HCC patients with high-risk recurrence after resection, warranting confirmation in largescale randomized clinical trials.
Authors
- Yonggang Wei (ORCID: https://orcid.org/0009-0006-3688-8795)
- Yongjie Zhou
- Wei Peng (ORCID: https://orcid.org/0000-0002-1604-5110)
- Diao Kong
- Fei Xie (ORCID: https://orcid.org/0000-0001-9879-6665)
- Tianfu Wen (ORCID: https://orcid.org/0000-0002-8260-7601)
- Yang Zou (ORCID: https://orcid.org/0000-0003-0887-7096)
- XiaoYun Zhang
- Zheyu Chen
- Junyi Shen (ORCID: https://orcid.org/0009-0007-0824-0833)
- Minghong Yao
- Chuan Li
- Yufu Peng
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- The First People's Hospital of Neijiang (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11550875/v1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- preprint